Lespedeza cuneata extract powder,
does it really help with Improved male climacteric symptoms?
research showsIn an eight-week double-blind RCT of 103 men, Lespedeza cuneata extract powder improved only AMS and ADAM symptom scores, while IIEF, testosterone, and SHBG did not differ from placebo. This was one manufacturer-specific subjective-outcome trial funded by Naturalway with company employees among the authors. A separate 88-person study tested a fenugreek-Lespedeza combination and is not standalone replication, resulting in C.
ads claimProduct descriptions may expand questionnaire improvement into higher testosterone, restored erectile function, improved prostate or urinary function, and general male vitality. These objective and functional outcomes did not improve over placebo in the direct single-ingredient trial.
Useful facts when choosing a product
- The single-ingredient trial product contained 625 mg of extract powder per tablet, taken as two tablets for 1,250 mg/day.
- The key positive outcomes were the patient-reported AMS and ADAM questionnaires.
- IIEF, IPSS, testosterone, SHBG, glucose and lipids, and BMI showed no significant between-group differences.
- Eight-week safety tests did not differ between groups, while long-term and rare-event data remain limited.
Chamgap Semantic Classification Code
Candidate index · review held
S.lespedeza-cuneata-extract-powder.UNK.male-climacteric-symptoms.improve.placeboSupplements and nutraceuticals > Lespedeza cuneata extract powder > Unknown > male climacteric symptoms > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The 2023 study by Kim and colleagues randomized 103 men with AMS scores of at least 37 and testosterone of 500 ng/dL or less to Lespedeza cuneata extract powder at 1,250 mg/day or placebo. At eight weeks, AMS and ADAM improved over placebo, while IIEF, IPSS, testosterone, SHBG, metabolic markers, and BMI showed no significant between-group differences. Naturalway funded the study and two authors were company employees. A 2018 trial by Park and colleagues reported selected positive findings with a 400 mg/day mixed extract of fenugreek seed and Lespedeza, but it cannot isolate the effect of Lespedeza alone.
Why this is classified as C (48)
The direct single-ingredient RCT supports an AMS and ADAM signal. It was one Naturalway-funded study with company employees among the authors, IIEF, testosterone, and SHBG were null, and the separate 88-person fenugreek combination is not standalone replication, resulting in C with 48 points.
Counterpoint. A signal for improved patient-reported climacteric symptoms over eight weeks remains in selected middle-aged men. This assessment does not extend that signal to increased hormones or improved sexual or urinary function.
Rejudgment record. Reassessment (cross-check reflected) — In one 103-person eight-week Naturalway-funded trial with company-employee authors, only AMS and ADAM were positive while IIEF, testosterone, and SHBG were null; an 88-person fenugreek-Lespedeza combination trial is not standalone replication
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| AMS and ADAM climacteric symptoms | C | Eight-week symptom scores improved over placebo in one manufacturer-supported RCT. |
| Testosterone and objective metabolic markers | D | The single-ingredient RCT found no between-group differences in testosterone, SHBG, glucose, or lipids. |
| Sexual function and urinary symptoms | D | IIEF and IPSS did not improve significantly over placebo. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Kim H et al. 2023 | Single-center randomized double-blind placebo-controlled trial | 8 | Funded by Naturalway; two employee authors | AMS, ADAM, IIEF, IPSS, testosterone, SHBG, and metabolic markers | AMS and ADAM improved, while IIEF, IPSS, hormones, blood tests, and BMI did not differ between groups. | Key |
| Park HJ et al. 2018 | Randomized double-blind placebo-controlled mixed-ingredient trial | 8 | Ingredient-company linked; company employee authors | AMS, testosterone, ADAM, IIEF, and metabolic markers | Selected positive findings were reported for a fenugreek-Lespedeza mixture, but the effect of Lespedeza alone cannot be isolated. | Indirect |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-11).
Final verification and publication gate: Codex · Evidence date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Lespedeza cuneata extract powder × Improved male climacteric symptoms — Evidence Grade C·48. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/lespedeza-cuneata-male-climacteric-symptoms/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.